RNDR
7.183
11-January-25 00:10:55
realtime
Instruments
-0.107
-1.47%
Today's range
7.12 - 7.278
ISIN
FXRNDRUSD
Source
GEMN
-
StockNews.com Upgrades BHP Group (NYSE:BHP) to Strong-Buy
11 Jan 2025 00:06:15 By Buzz FX
-
Insider Buying: Potbelly Co. (NASDAQ:PBPB) Major Shareholder Buys 7,600 Shares of Stock
11 Jan 2025 00:05:14 By Buzz FX
-
Christopher C. Colson Sells 1,370 Shares of Texas Roadhouse, Inc. (NASDAQ:TXRH) Stock
11 Jan 2025 00:05:14 By Buzz FX
-
Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares
11 Jan 2025 00:05:14 By Buzz FX
-
Palantir Technologies Inc. (NASDAQ:PLTR) Director Sells $286,520.00 in Stock
11 Jan 2025 00:05:14 By Buzz FX
-
MeiraGTx Holdings plc (NASDAQ:MGTX) CEO Sells $231,878.33 in Stock
11 Jan 2025 00:05:14 By Buzz FX
-
William M. Sheriff Sells 24,000 Shares of enCore Energy Corp. (NASDAQ:EU) Stock
11 Jan 2025 00:05:14 By Buzz FX
-
Arcellx, Inc. (NASDAQ:ACLX) Insider Sells $261,820.57 in Stock
11 Jan 2025 00:05:14 By Buzz FX
-
Hang Seng Index Tumbles Amid US-China Tensions and Weak China Data - Weekly Recap
11 Jan 2025 00:04:18 By Buzz FX
-
Boot Barn (NYSE:BOOT) Updates Q3 Earnings Guidance
11 Jan 2025 00:04:14 By Buzz FX
-
What BofA says it would take for the Fed's next rate move to be a hike
11 Jan 2025 00:03:26 By Buzz FX
-
China's auto exports expected to slow amid tariff pressures and stalling EV growth
11 Jan 2025 00:01:23 By Buzz FX
-
Health literacy rate shows steady rise - Chinadaily.com.cn
10 Jan 2025 19:46:23 By Buzz FX
-
S&P 500 hit in worst day since 'post-Fed tantrum'
10 Jan 2025 19:45:24 By Buzz FX
-
Wedbush Reiterates "Neutral" Rating for Intellia Therapeutics (NASDAQ:NTLA)
10 Jan 2025 19:41:14 By Buzz FX
-
Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY)
10 Jan 2025 19:41:14 By Buzz FX
-
Disc Medicine (NASDAQ:IRON) Earns "Outperform" Rating from Wedbush
10 Jan 2025 19:41:14 By Buzz FX
-
Wedbush Reaffirms Outperform Rating for Mersana Therapeutics (NASDAQ:MRSN)
10 Jan 2025 19:41:14 By Buzz FX
-
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush
10 Jan 2025 19:41:14 By Buzz FX
-
iTeos Therapeutics' (ITOS) "Outperform" Rating Reaffirmed at Wedbush
10 Jan 2025 19:41:14 By Buzz FX